Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Eupraxia Pharmaceuticals ( (TSE:EPRX) ).
Eupraxia Pharmaceuticals reported a wider fourth-quarter 2025 net loss of $16.7 million, compared with $7.5 million a year earlier, as it ramped research and development spending on its lead EP-104GI program and expanded general and administrative costs. The company ended 2025 with $80.5 million in cash, bolstered by recent financings including a February 2026 equity and pre-funded warrant offering that raised about $63.2 million, which it expects will fund operations into the second half of 2028.
Operationally, Eupraxia highlighted additional 52-week follow-up data and positive biopsy-based tissue health results from its RESOLVE trial in eosinophilic esophagitis, supporting the potential of EP-104GI and setting up multiple clinical readouts in 2026. Management is also monitoring evolving U.S.-Canada tariff dynamics due to its U.S.-based manufacturing arrangements, assessing potential direct and indirect impacts on its supply chain while maintaining U.S. dollar balances to manage currency and trade-related risks.
The most recent analyst rating on (TSE:EPRX) stock is a Buy with a C$19.00 price target. To see the full list of analyst forecasts on Eupraxia Pharmaceuticals stock, see the TSE:EPRX Stock Forecast page.
Spark’s Take on TSE:EPRX Stock
According to Spark, TipRanks’ AI Analyst, TSE:EPRX is a Neutral.
The score is held back primarily by weak financial performance (pre-revenue, ongoing losses and cash burn), partially offset by a conservatively levered balance sheet. Technicals are the main positive, showing a clear uptrend and constructive momentum, while valuation is constrained by negative earnings and no dividend data.
To see Spark’s full report on TSE:EPRX stock, click here.
More about Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company developing locally delivered, extended-release therapeutics targeting areas of high unmet medical need. Its proprietary Diffusphere polymer-based microsphere technology is designed to enable targeted, controlled drug delivery of existing and novel drugs over an extended duration of effect.
Average Trading Volume: 92,506
Technical Sentiment Signal: Buy
Current Market Cap: C$533.6M
For detailed information about EPRX stock, go to TipRanks’ Stock Analysis page.